Payment overview · 2025
General Payments
$318.59
17 reported records · 10 companies
Healthcare provider profile · identity verified
Floyd Clinton Watson, MD
Allopathic & Osteopathic Physicians|Family Medicine · MCGREGOR, TX · NPI 1447268164
Verified facts
What the public records show
CMS Open Payments records show Floyd Clinton Watson, MD received $318.59 in general payments during 2025 across 17 reported records.
PFIZER INC. accounted for 19.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 209 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $61.02 | 19.1% | 3 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $41.85 | 13.1% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $33.51 | 10.5% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $33.18 | 10.4% | 1 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $32.07 | 10.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $29.10 | 9.1% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $28.45 | 8.9% | 2 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $22.18 | 7.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $21.50 | 6.8% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $15.73 | 4.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $318.59 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $61.02 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $61.02 | 3 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $41.85 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $39.07 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $33.51 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $33.18 | 1 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $32.07 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $32.07 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $29.10 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $29.10 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $28.45 | 2 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $22.18 | 1 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $21.95 | 1 | 2025 |
Source payment records
|
|||||
| TRUMENBA Normalized: trumenba |
Biological | PFIZER INC. | $21.95 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $21.50 | 1 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $15.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 70 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
132 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
70 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
209 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 492 | 89 |
| Levothyroxine Sodium | Levothyroxine Sodium | 392 | 66 |
| Gabapentin | Gabapentin | 328 | 63 |
| Amlodipine Besylate | Amlodipine Besylate | 309 | 67 |
| Potassium Chloride | Potassium Chloride | 307 | 43 |
| Furosemide | Furosemide | 302 | 61 |
| Lisinopril | Lisinopril | 274 | 61 |
| Losartan Potassium | Losartan Potassium | 249 | 44 |
| Donepezil Hcl | Donepezil Hcl | 238 | 32 |
| Eliquis | Apixaban | 209 | 26 |
| Sertraline Hcl | Sertraline Hcl | 207 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 192 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 189 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 177 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 169 | 37 |
| Carvedilol | Carvedilol | 168 | 39 |
| Buspirone Hcl | Buspirone Hcl | 165 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 159 | 29 |
| Metformin Hcl | Metformin Hcl | 154 | 42 |
| Memantine Hcl | Memantine Hcl | 153 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 152 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 137 | 28 |
| Mirtazapine | Mirtazapine | 133 | 32 |
| Jardiance | Empagliflozin | 132 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 120 | 48 |
| Omeprazole | Omeprazole | 110 | 26 |
| Metformin Hcl Er | Metformin Hcl | 108 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 104 | 26 |
| Trazodone Hcl | Trazodone Hcl | 104 | 24 |
| Simvastatin | Simvastatin | 85 | 23 |
| Famotidine | Famotidine | 81 | 20 |
| Januvia | Sitagliptin Phosphate | 79 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 77 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 76 | 21 |
| Tramadol Hcl | Tramadol Hcl | 75 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 72 | 29 |
| Mounjaro | Tirzepatide | 70 | 14 |
| Spironolactone | Spironolactone | 68 | suppressed |
| Ozempic | Semaglutide | 67 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 61 | 28 |
| Paroxetine Hcl | Paroxetine Hcl | 61 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 59 | suppressed |
| Myrbetriq | Mirabegron | 54 | suppressed |
| Ezetimibe | Ezetimibe | 52 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 51 | 21 |
| Levetiracetam | Levetiracetam | 51 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | 16 |
| Alendronate Sodium | Alendronate Sodium | 50 | 16 |
| Finasteride | Finasteride | 49 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | 11 |
| Torsemide | Torsemide | 48 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 47 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 46 | suppressed |
| Bupropion Xl | Bupropion Hcl | 45 | suppressed |
| Risperidone | Risperidone | 43 | suppressed |
| Celecoxib | Celecoxib | 41 | 12 |
| Prednisone | Prednisone | 41 | 22 |
| Allopurinol | Allopurinol | 40 | 12 |
| Aripiprazole | Aripiprazole | 40 | suppressed |
| Cephalexin | Cephalexin | 39 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | 14 |
| Clonazepam | Clonazepam | 37 | 13 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 36 | 11 |
| Meloxicam | Meloxicam | 36 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | suppressed |
| Ondansetron Odt | Ondansetron | 35 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 34 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 31 | suppressed |
| Pregabalin | Pregabalin | 31 | suppressed |
| Topiramate | Topiramate | 31 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 30 | suppressed |
| Lorazepam | Lorazepam | 30 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 28 | 11 |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 26 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Levemir Flexpen | Insulin Detemir | 26 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 26 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Nifedipine Er | Nifedipine | 25 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Primidone | Primidone | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 22 | suppressed |
| Gemfibrozil | Gemfibrozil | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Lactulose | Lactulose | 21 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 21 | suppressed |
| Novolog | Insulin Aspart | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Azithromycin | Azithromycin | 20 | 16 |
| Felodipine Er | Felodipine | 20 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 20 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 18 |
| Candesartan Cilexetil | Candesartan Cilexetil | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Febuxostat | Febuxostat | 18 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 16 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 15 |
| Atenolol | Atenolol | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Nystop | Nystatin | 14 | suppressed |
| Alprazolam | Alprazolam | 13 | suppressed |
| Naproxen | Naproxen | 13 | 11 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 13 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 13 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 13 | suppressed |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Incontrol Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | 11 |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $318.59 · 17 records | PFIZER INC. | ABRYSVO, Auvelity, BEYFORTUS, BREZTRI, COMIRNATY, Dexcom G6 Transmitter, MOUNJARO, NEXPLANON, Natroba, PENBRAYA, PREVNAR 20, QUTENZA, Spinosad, TRUMENBA, The Cologuard Plus Collection Kit, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error